• Bay 11-7821 (BAY 11-7082) in Cancer and Inflammatory Pathway

  2026-07-08

  Bay 11-7821 (BAY 11-7082) is a selective IKK inhibitor that empowers robust and reproducible workflows for dissecting NF-κB-driven signaling in cancer and inflammation studies. This guide details optimized experimental protocols, troubleshooting strategies, and translational applications inspired by the latest immuno-oncology findings.

• MLN4924 HCl Salt: Decoding Neddylation in Viral Immunity

  2026-07-07

  This thought-leadership article explores how MLN4924 HCl salt, a potent NEDD8-activating enzyme inhibitor, enables translational researchers to dissect viral immune evasion, specifically through cullin-RING ligase and ubiquitin-proteasome pathway manipulation. Integrating recent mechanistic findings on RIPK3 degradation by orthopoxviruses, we provide a strategic guide to protocol design, competitive landscape, and future directions for targeting neddylation in cancer and antiviral research.

• TMEM16F in Kupffer Cells Suppresses Liver Injury in Listeria

  2026-07-07

  This study reveals that TMEM16F, a lipid scramblase, is essential in Kupffer cells for protecting the liver from Listeria monocytogenes-induced inflammation and metabolic disruption. By using cell type-specific knockout models, the research uncovers how TMEM16F-mediated membrane repair in liver macrophages limits cell death and tissue damage, providing mechanistic insights with implications for necroptosis and programmed necrotic cell death research.

• cgSHAPE-seq Maps RNA-Degrading Chimera Sites in SARS-CoV-2 5

  2026-07-06

  This study introduces cgSHAPE-seq, a chemical-guided sequencing method that precisely identifies the binding sites of small molecules on structured viral RNA. By mapping how coumarin-based chimeras target the SARS-CoV-2 5’ untranslated region, the work enables rational design of RNA-targeting antivirals and advances molecular tools for studying RNA–ligand interactions.

• BI 2536: Revealing PLK1 Checkpoint Control for Cancer Resear

  2026-07-06

  Explore how BI 2536, a potent PLK1 inhibitor, uniquely elucidates mitotic checkpoint regulation and advances cancer research. This article offers a deep dive into the molecular mechanisms and practical assay implications that set BI 2536 apart.

• 3-Aminobenzamide (PARP-IN-1): Applied Workflows & Experiment

  2026-07-05

  3-Aminobenzamide (PARP-IN-1) empowers researchers to dissect poly (ADP-ribose) polymerase pathways with reliable, low-toxicity inhibition at nanomolar concentrations. This guide bridges cardiovascular, metabolic, and host-pathogen research, offering stepwise protocols, troubleshooting, and data-backed insights for maximizing reproducibility and biological relevance.

• Multiplexed ACE2 Libraries Reveal SARS-CoV-2 Variant Recepto

  2026-07-04

  This study introduces a high-throughput pseudotyped virus assay to systematically map how SARS-CoV-2 spike variants interact with a diverse set of ACE2 receptor variants. The findings illuminate how viral evolution subtly alters compatibility with human ACE2 while more dramatically expanding cross-species receptor usage, informing both virology and host-range research.

• Ciprofloxacin Hydrochloride: Advanced Workflows & Antiparasi

  2026-07-03

  Ciprofloxacin hydrochloride, a fluoroquinolone antibiotic, is redefining experimental design by bridging robust antibacterial mechanisms with emerging antiparasitic workflows. Recent studies and workflow innovations enable researchers to leverage its DNA replication inhibition and immunomodulatory properties, offering unique troubleshooting paths for both classic and translational applications.

• EV-Transferred ACLY Drives TAM Differentiation in Liver Canc

  2026-07-03

  This study uncovers how hepatocellular carcinoma cells use extracellular vesicles to deliver ATP-citrate lyase (ACLY) to monocytes, inducing their differentiation into immunosuppressive tumor-associated macrophages. The findings reveal an EV-mediated metabolic axis as a promising target for improving immunotherapy in liver cancer.

• Tris(2-carboxyethyl) Phosphine Hydrochloride in Protein Dige

  2026-07-02

  Tris(2-carboxyethyl) phosphine hydrochloride (TCEP hydrochloride) transforms protein analysis workflows with its thiol-free, odorless, and highly selective disulfide bond reduction—enabling enhanced protein digestion and robust redox chemistry. Its stability and versatility outshine conventional reductants, making it indispensable for advanced proteomics and DNA-protein crosslink research.

• Applied Insights with the TUNEL Apoptosis Detection Kit

  2026-07-02

  The TUNEL Apoptosis Detection Kit (DAB) empowers researchers to achieve precise, reproducible DNA fragmentation detection in both tissue and cell models. By leveraging this kit’s streamlined workflow and robust performance, scientists can confidently dissect programmed cell death mechanisms with clarity and efficiency.

• Cerulenin Inhibits Leucomycin Biosynthesis via Polyketide Pa

  2026-07-01

  This study demonstrates that cerulenin, a fatty acid synthesis inhibitor, specifically blocks the biosynthesis of leucomycin, a 16-membered macrolide antibiotic, in Streptomyces kitasatoensis. The findings clarify the polyketide origin of macrolide antibiotics and provide mechanistic insights relevant to antibacterial drug resistance and the development of new antibiotic production strategies.

• GPNMB-Based Multimodal Model Predicts Immunotherapy Response

  2026-07-01

  This study introduces a multimodal model leveraging circulating GPNMB and tumor microenvironment features to accurately predict immunotherapy response in esophageal squamous cell carcinoma (ESCC). By elucidating how tumor-derived sGPNMB drives CD8+ T cell exhaustion, the research provides a clinically scalable approach for patient stratification and therapy optimization.

• SMYD2 Inhibition Mitigates Cisplatin-Induced Renal Fibrosis

  2026-06-30

  This study demonstrates that pharmacological inhibition of SMYD2, using substrate-competitive inhibitors such as AZ505, can protect against cisplatin-induced renal fibrosis and inflammation in preclinical models. The findings reveal a mechanistic link between SMYD2 activity, epithelial-mesenchymal transition, and pro-fibrotic signaling, suggesting new directions for epigenetic regulation research in kidney disease.

• U 46619: Precision Platelet Aggregation Inducer in Vascular

  2026-06-30

  U 46619 (11,9 epoxymethano-prostaglandin H2) delivers unrivaled reproducibility as a selective platelet aggregation inducer and TP receptor agonist, making it indispensable for translational cardiovascular and renal studies. Discover evidence-based workflows, protocol optimizations, and troubleshooting that elevate your experimental rigor beyond the standard toolkit.

451 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page